Pier Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Pier Capital’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-75,000	Closed	-$3.12M	–	136
2025 Q3	$3.12M	Sell	75,000 -67,611	-47%	-$2.16M	0.49%	94
2025 Q2	$4.1M	Buy	142,611 +29,199	+26%	+$902K	0.63%	77
2025 Q1	$3.8M	Buy	113,412 +1,413	+1%	+$52.8K	0.64%	76
2024 Q4	$5.73M	Buy	111,999 +3,638	+3%	+$204K	0.82%	74
2024 Q3	$5.54M	Sell	108,361 -184	-0.2%	-$9.49K	0.78%	71
2024 Q2	$4.86M	Sell	108,545 -8,025	-7%	-$371K	0.72%	73
2024 Q1	$5.46M	Sell	116,570 -33	-0%	-$1.29K	0.75%	67
2023 Q4	$4.15M	Buy	+116,603	New	+$3.58M	0.59%	82

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Pier Capital's CRNX Position: Q4 2025 in Review

Pier Capital sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2025, closing a stake of 75,000 shares — an estimated $3.12M sold.

Pier Capital first reported a position in CRNX in Q4 2023 and held it in 8 quarters. The position peaked at $5.73M in Q4 2024. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

Pier Capital reported no remaining Crinetics Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Pier Capital sold 75,000 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $3.12M.
Pier Capital first reported a position in Crinetics Pharmaceuticals in Q4 2023 and held it in 8 quarters.
Pier Capital's Crinetics Pharmaceuticals position peaked at $5.73M in Q4 2024.
240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on Pier Capital's 13F filing for Q4 2025, filed 3 Feb 2026.